What is a stock summary page? Click here for an overview.
Business Description
Ultragenyx Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US90400D1081
Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.12 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.49 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.1 | |||||
| 3-Year EBITDA Growth Rate | 5.1 | |||||
| 3-Year EPS without NRI Growth Rate | -0.2 | |||||
| 3-Year FCF Growth Rate | 7.6 | |||||
| 3-Year Book Growth Rate | -40.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 61.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 30.56 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 100 | |||||
| 6-1 Month Momentum % | 53 | |||||
| 12-1 Month Momentum % | 53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 2.24 | |||||
| Cash Ratio | 1.77 | |||||
| Days Inventory | 188.72 | |||||
| Days Sales Outstanding | 64.46 | |||||
| Days Payable | 207.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | -11.95 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.3 | |||||
| Operating Margin % | -95.67 | |||||
| Net Margin % | -101.6 | |||||
| FCF Margin % | -74.43 | |||||
| ROE % | -196.24 | |||||
| ROA % | -38.16 | |||||
| ROIC % | -68.13 | |||||
| 3-Year ROIIC % | -155.43 | |||||
| ROC (Joel Greenblatt) % | -181.13 | |||||
| ROCE % | -41.83 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.53 | |||||
| PB Ratio | 12.37 | |||||
| Price-to-Tangible-Book | 97.51 | |||||
| EV-to-EBIT | -5.24 | |||||
| EV-to-Forward-EBIT | -6.66 | |||||
| EV-to-EBITDA | -5.64 | |||||
| EV-to-Forward-EBITDA | -6.73 | |||||
| EV-to-Revenue | 4.72 | |||||
| EV-to-Forward-Revenue | 5.09 | |||||
| EV-to-FCF | -6.09 | |||||
| Price-to-GF-Value | 0.65 | |||||
| Earnings Yield (Greenblatt) % | -19.08 | |||||
| FCF Yield % | -13.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Ultragenyx Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 10,574.37 | ||
| EPS (TTM) (MXN) | -117.297 | ||
| Beta | -1.26 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.07 | ||
| Volatility % | 53 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (MXN) | 0.002699 | ||
| 20-Day SMA (MXN) | 1150.56 | ||
| 12-1 Month Momentum % | 53 | ||
| 52-Week Range (MXN) | 751.98 - 1150.56 | ||
| Shares Outstanding (Mil) | 93.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ultragenyx Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ultragenyx Pharmaceutical Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ultragenyx Pharmaceutical Inc Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc(MEX:RARE)'s stock price today?
The current price of MEX:RARE is MXN1150.56. The 52 week high of MEX:RARE is MXN1150.56 and 52 week low is MXN751.98.
When is next earnings date of Ultragenyx Pharmaceutical Inc(MEX:RARE)?
The next earnings date of Ultragenyx Pharmaceutical Inc(MEX:RARE) is 2025-05-02 Est..
Does Ultragenyx Pharmaceutical Inc(MEX:RARE) pay dividends? If so, how much?
Ultragenyx Pharmaceutical Inc(MEX:RARE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers